Francoise Bridey
Overview
Explore the profile of Francoise Bridey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Windyga J, Guillet B, Rugeri L, Fournel A, Stefanska-Windyga E, Chamouard V, et al.
Thromb Haemost
. 2022 Jun;
122(8):1304-1313.
PMID: 35642281
Background: A plasma-derived factor VIII product (pdFVIII; Factane 100 or 200 IU/mL) and a plasma-derived von Willebrand factor product (pdVWF; Wilfactin 100 IU/mL) are approved for replacement therapy by intravenous...
2.
Gouider E, Klukowska A, Maes P, Platokouki H, Pujol S, Henriet C, et al.
Blood Transfus
. 2022 May;
21(1):83-92.
PMID: 35543677
Background: Plasma-derived von Willebrand factor (VWF) (Wilfactin, LFB, France) was developed for prophylaxis and treatment of haemorrhages in both adults and adolescents with von Willebrand disease (VWD). Replacement therapy in...
3.
Goudemand J, Bridey F, Claeyssens S, Itzhar-Baikian N, Harroche A, Desprez D, et al.
J Thromb Haemost
. 2020 May;
18(8):1922-1933.
PMID: 32445594
Background: A triple-secured plasma-derived von Willebrand factor (pdVWF) almost devoid of factor VIII (FVIII):WILFACTIN , was approved in France in 2003, and then in other countries for the treatment of...
4.
Djambas Khayat C, El Khorassani M, Aytac S, Harroche A, Dahmane A, Pujol S, et al.
Thromb Haemost
. 2020 May;
120(6):957-967.
PMID: 32392604
Objective: To date, the use of a fibrinogen concentrate (FC) administered in children with inherited fibrinogen deficiency is poorly documented. Treatment modalities may differ from those of adults. The aim...
5.
Bellon A, Fuseau E, Roumanie O, Lamazure J, Stevens W, Dahmane A, et al.
Br J Clin Pharmacol
. 2019 Oct;
86(2):329-337.
PMID: 31658379
Aims: The pharmacokinetics (PK) of a triple-secured fibrinogen concentrate (FC) was assessed in patients ≥40 kg by noncompartmental analysis over a period of 14 days with multiple blood samples. Limited...
6.
Djambas Khayat C, El Khorassani M, Lambert T, Gay V, Barthez-Toullec M, Lamazure J, et al.
J Thromb Haemost
. 2019 Jan;
17(4):635-644.
PMID: 30661302
Essentials A novel fibrinogen concentrate was evaluated in patients with congenital fibrinogen deficiency. An open-label, phase 2-3 trial studied pharmacology, efficacy, and safety in patients >6 years. The product offers...
7.
Bridey F, Negrier C, Duval C, Ariens R, Moerloose P, Casini A
Haematologica
. 2018 Sep;
104(3):e111-e113.
PMID: 30262556
No abstract available.
8.
Gueguen P, Galinat H, Blouch M, Bridey F, Duchemin J, Le Gal G, et al.
Br J Haematol
. 2011 Nov;
156(2):245-51.
PMID: 22098495
Bleeding risk is not predictable in patients with factor XI (FXI; F11) deficiency. In this prospective study, our objectives were to determine the biological determinants for bleeding risk in patients...